CDXC - יתרת חוב לטווח ארוך של החברה ChromaDex

Current price action for ChromaDex Corporation (CDXC) reflects the business development of implementing innovations in cellular longevity through the Tru Niagen brand and retail partnerships. Production efficiency is driven by the automation of packaging lines and AI-powered composition monitoring, which reduces costs. Long-term liabilities stand at 0.00 as the company scales wholesale Niagen shipments and expands e-commerce based on clinical research.

Long-term debt reflects the total obligations with a maturity horizon of more than one year, determining the issuer's financial stability. A decrease in this metric indicates deleveraging, while an increase suggests expansion or refinancing. By analyzing the dynamics of the firm's long-term borrowings, an investor assesses liquidity risk amid changing interest rates. A stable level of borrowing for ChromaDex Corporation (CDXC) supports the modernization of packaging lines, which ensures the uninterrupted operation of ingredient production plants.